Dietary Supplement Health Claims Data Requested By FDA
This article was originally published in The Tan Sheet
Executive Summary
Scientific data or related information on four potential health claims for dietary supplements is solicited by FDA in a Sept. 8 Federal Register notice. The request is the agency's first public effort to deal with the recent D.C. federal appeals court decision in the Pearson v. Shalala case.
You may also be interested in...
FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs
A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.
FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs
A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.
FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs
A revision of FDA's strategy for dealing with the four health claims the agency was ordered to reconsider under the Pearson v. Shalala decision is requested by plaintiffs' counsel Jonathan Emord (Washington, D.C.-based Emord & Associates) in a Sept. 23 letter to the agency. The letter asks FDA to notify the plaintiffs of such changes by Oct. 15.